Literature DB >> 12901281

Use of low-energy X-rays in the treatment of superficial nonmelanomatous skin cancers.

William R Bodner1, Basil S Hilaris, Mehran Alagheband, Bijan Safai, Constance A Mastoras, Sharad Saraf.   

Abstract

The Photon Radiosurgery System (PRS), developed by the Photoelectron Corporation in Lexington, Massachusetts, produces low-energy x-rays from the tip of a needle-like probe at a high dose-rate. This portable device can be located directly over the target volume, delivering a uniform dose while sparing surrounding normal structures. To evaluate its radiotherapeutic profile, a prospective phase I Food and Drug Administration trial was performed utilizing this device in the management of nonmelanomatous skin cancers. Target doses ranged from 10 Gray in one fraction to 30 Gray in three weekly fractions. Thirty-eight lesions in 18 patients were treated. The overall completed response rate for all histologies at 12 months was 83%. No significant acute or late morbidity was encountered. Our results to date demonstrate that low-energy x-rays produced by the PRS were as effective in managing nonmelanomatous skin tumors as other radiation treatment modalities without the need for cumbersome shielding or radiation precautions.

Entities:  

Mesh:

Year:  2003        PMID: 12901281     DOI: 10.1081/cnv-120018226

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  2 in total

1.  Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids.

Authors:  Mark S Nestor; Brian Berman; David Goldberg; Armand B Cognetta; Michael Gold; William Roth; Clay J Cockerell; Brad Glick
Journal:  J Clin Aesthet Dermatol       Date:  2019-02-01

2.  Keloid Management: A Retrospective Case Review on a New Approach Using Surgical Excision, Platelet-Rich Plasma, and In-office Superficial Photon X-ray Radiation Therapy.

Authors:  Michael E Jones; Cherrell Hardy; Julie Ridgway
Journal:  Adv Skin Wound Care       Date:  2016-07       Impact factor: 2.347

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.